Summit Therapeutics Inc. Overview
Pro stress-test →Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of novel therapeutic treatments. The company's lead candidate, ivonescimab, is a bispecific antibody in Phase III clinical trials for non-small cell lung cancer treatment, with over 3,000 patients globally treated across trials.
Strategic Profile
Pro stress-test →Summit leverages a partnership with Akeso Inc. to advance ivonescimab development across multiple tumor types, with three Phase III trials (HARMONi, HARMONi-3, HARMONi-7) underway in the US, Canada, Europe and other territories. The company benefits from Akeso's established clinical data from China and positions itself as a leader in bringing innovative oncology therapies to unmet medical needs.
Competitive Landscape
Pro stress-test →Summit competes in the immuno-oncology space against established players including Merck (Keytruda), Bristol Myers Squibb (Opdivo), Regeneron/Sanofi (Libtayo), and emerging biotech. The company's dual-mechanism bispecific antibody approach differentiates it from standard checkpoint inhibitors, though regulatory approval remains critical for market penetration.
Industry Context
Summit Therapeutics Inc. operates in Biopharmaceutical/Oncology.
Key facts
Founded: 2003 · Headquarters: Miami, Florida · Revenue: $313K · Market cap: $16.8B